背景:多发性骨髓瘤(MM)是仅次于非霍奇金淋巴瘤的第二大流行血癌。它是通过异常单克隆免疫球蛋白的过量产生来鉴定的,这可能导致各种临床症状,如破坏性骨病变,肾功能不全,贫血,和免疫缺陷。本研究旨在评估血清羧基末端胶原交联1(CTX-1)的水平,Fibulin-1,维生素D3,LDH,MM患者的白蛋白和白蛋白及其对早期诊断的意义。
方法:本研究包括30名健康对照(11名男性,19名女性)和60名多发性骨髓瘤患者(37名男性和23名女性),年龄在40-60岁之间。收集5毫升血样并储存在-20℃。之后,酶联免疫吸附测定(ELISA)试剂盒用于评估CTX-1,Fibulin-1和维生素D3的浓度.此外,使用自动生物化学分析仪测定LDH和白蛋白水平。
结果:这项研究表明,大多数多发性骨髓瘤患者的年龄在51至60岁之间。与健康对照组相比,多发性骨髓瘤患者的血清CTX-1,Fibulin-1和LDH浓度显着升高。相比之下,MM患者的血清维生素D3水平显着降低。
结论:我们的结果表明男性多发性骨髓瘤的发病率高于女性。此外,与健康对照组相比,多发性骨髓瘤患者的血清CTX-1和Fibulin-1浓度显着升高,表明它们早期检测和作为治疗靶点的潜力。
BACKGROUND: Multiple myeloma (MM) is the second most prevalent blood cancer after non-Hodgkin lymphoma. It is identified by the excessive production of abnormal monoclonal immunoglobulins, which can result in various clinical symptoms such as destructive bone lesions, renal dysfunction, anemia, and immunodeficiency. The current study aims to evaluate the serum levels of carboxy-terminal collagen crosslinks 1 (CTX-1), Fibulin-1, vitamin D3, LDH, and albumin in MM patients and their significance for early diagnosis.
METHODS: This study included 30 healthy controls (11 males, 19 females) and 60 patients with multiple myeloma (37 males and 23 females), aged between 40-60 years. Five-milliliter blood samples were collected and stored at -20°C. Afterward, enzyme-linked immunosorbent assay (ELISA) kits were used to estimate the concentrations of CTX-1, Fibulin-1, and vitamin D3. Additionally, LDH and albumin levels were determined using the automated biochemistry analyzer.
RESULTS: This study revealed that the majority of patients with multiple myeloma are between the ages of 51 and 60 years. The serum concentrations of CTX-1, Fibulin-1, and LDH were significantly increased in the multiple myeloma patients compared to the healthy control group. In contrast, the serum level of vitamin D3 was significantly decreased in patients with MM.
CONCLUSIONS: Our results indicate that the incidence of multiple myeloma is higher in males than in females. Additionally, the serum concentrations of CTX-1 and Fibulin-1 were significantly higher in the multiple myeloma patients compared to the healthy control group, indicating their potential for early detection and as therapeutic targets.